Evommune EVMN 深 沪
等待开盘 07-09 09:30:00 美东时间
13.13
-0.210
-1.57%
华盛通- 最 高14.01
- 今 开13.105
- 成交量 39.02万股
- 最 低 12.96
- 昨 收 13.34
- 总市值 4.73亿
- 52周最高 33.20
- 市盈率 静 --
- 换手率 1.08%
- 52周最低 12.07
- 委 比 20.00%
- 总股本 3601.84万
- 历史最高 33.20
- 量 比 0.65
- 振 幅 7.87%
- 历史最低 12.07
- 每 手 1
- 风险率 3.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.
06-30 20:56
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst RJ Milligan downgraded Alpine Income Property Trust Inc (NYSE:PINE) from Outperform...
06-30 20:51
HC Wainwright & Co. Downgrades Evommune to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Evommune (NYSE:EVMN) from Buy to Neutral.
06-30 18:41
William Blair Downgrades Evommune to Market Perform
William Blair analyst Matt Phipps downgrades Evommune (NYSE:EVMN) from Outperform to Market Perform.
06-30 00:52
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday. Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading. Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves’ disease. B of A Securi...
06-29 20:11
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
HC Wainwright & Co. Reiterates Buy on Evommune, Maintains $50 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Buy and maintains $50 price target.
05-26 18:53
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
